Results 41 to 50 of about 27,659 (185)

De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y12 Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis

Reviews in Cardiovascular Medicine, 2022
Background: Dual antiplatelet therapy (DAPT) with potent P2Y12 inhibitor is the cornerstone of acute coronary syndrome (ACS) management. Balancing the effects of different strategies of antiplatelet therapy including DAPT de-escalation, potent P2Y12 ...
Jing-Wen Ding, Yang Chen, Zuo-Zhong Yu, Yuan-Bin Zhao, Kun-Peng Fan, Xiong-Da Yao, Long-Long Hu, Yan-Hui Liao, Tian-Hua Deng, Yi Xia, Han-Hui Liao, Ren-Qiang Yang   +11 more
doaj   +1 more source

The future of P2Y12 receptor antagonists

, 2015
Platelet P2Y12 inhibitors have become a central component of the treatment strategy for patients with atherothrombosis due to the importance of platelet P2Y12 receptors in arterial thrombosis.
Thomas, Mark R; id_orcid, Storey, Robert F   +1 more
core   +1 more source

Pengaruh Polimorfisme P2Y12 Pada Penggunaan Antiplatelet Terhadap Kejadian Stroke Berulang

, 2023
Stroke merupakan keadaan defisit neurologik secara fokal dan global. Salah satu pengobatan yang digunakan adalah antiplatelet seperti clopidogrel yang dapat menghambat pembentukan trombus yang bisa menurunkan angka kematian. Dalam perkembangan pengobatan,
Raising, Rahmawati, hermawatiningsih, oktaviarika dewi   +1 more
core   +1 more source

Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV

Advanced Science, EarlyView.
Knowledge of human CNS immune responses to AAV‐based gene therapies remains limited due to the lack of immune‐competent human models. Here, a hiPSC‐derived 3D neuroimmune platform integrating neurospheroids and microglia is established using stirred‐tank bioreactors.
Catarina M. Gomes, Gabriela Silva, Mafalda Aleixo, Marta Gomes, Daniel Simão, Stephan J. Holtkamp, Diana D. Lobo, Pradeep Harish, Rosalind Jenkins, Lekh N. Dahal, Rui J. Nobre, Luís de Pereira de Almeida, Mark Trautwein, Paula M. Alves, Catarina Brito   +14 more
wiley   +1 more source

Long non-coding RNA metallothionein 1 pseudogene 3 promotes p2y12 expression by sponging miR-126 to activate platelet in diabetic animal model

Platelets, 2019
Platelet hyperaggregation and hypercoagulation are associated with increase of thrombogenic risk, especially in patients with type 2 diabetes (T2D).
Ming Zhou, Meng Gao, Yanwei Luo, Rong Gui, Hongwen Ji   +4 more
doaj   +1 more source

VlPAG/DRN Microglia Drive Neuropathic Pain‐Induced Depression via a Defined Neuroimmune Axis

Advanced Science, EarlyView.
Peripheral nerve injury (SNI) induces neuropathic pain, activates midbrain microglia, and triggers an NLRP3–IL‐1β–dependent inflammatory cascade. IL‐1β signals through IL‐1R1 on vlPAG/DRN VGLUT2+ neurons (vlPAG/DRNGlu), inducing hyperexcitability and driving the vlPAG/DRNGlu→BNSTGABA circuit to produce the affective component of neuropathic pain ...
Jing Yang, Bing‐Jie Tang, Jia‐Yi Li, Shu‐Lan Xie, Shumin Duan, Junping Chen, Shengmei Zhu, Zhen‐Zhong Xu   +7 more
wiley   +1 more source

Standardization of measurement and reporting of medication adherence using the TEN‐SPIDERS tool for claims data

British Journal of Clinical Pharmacology, EarlyView.
This study provides the first open‐source tool to implement the complete TEN‐SPIDERS framework in linked datasets for the determination of the PDC for medication adherence. The TEN‐SPIDERS tool enables transparent, reproducible medication adherence research through automated reporting of all calculation parameters and flexible customization options ...
Adam C. Livori, Tzu‐Yung Kuo, Jenni Ilomäki, Monique F. Kilkenny, Stella Talic, Zanfina Ademi, J. Simon Bell, Jedidiah I. Morton, Lachlan L. Dalli   +8 more
wiley   +1 more source

Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background P2Y12 inhibitor medications are critical following percutaneous coronary intervention (PCI); however, adherence remains suboptimal. Our objective was to assess the effectiveness of a multifaceted intervention to improve P2Y12 inhibitor ...
P. Michael Ho, Colin I. O’Donnell, Marina McCreight, Anthony A. Bavry, Hayden B. Bosworth, Saket Girotra, P. Michael Grossman, Christian Helfrich, Faisal Latif, David Lu, Michael Matheny, Kreton Mavromatis, Jose Ortiz, Amitabh Parashar, Devona M. Ratliff, Gary K. Grunwald, Michael Gillette, Hani Jneid   +17 more
doaj   +1 more source

Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist

Molecules, 2016
The P2Y12 receptor is critical for platelet activation and is an attractive drug target for the prevention of atherothrombotic events. Despite the proven antithrombotic efficacy of P2Y12 inhibitors, these thienopyridine scaffolds are prodrugs that lack ...
Young Ha Ahn, Joo-Youn Lee, Hee Dong Park, Tae Hun Kim, Min Chul Park, Gildon Choi, Sunghoon Kim   +6 more
doaj   +1 more source

Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018

American Heart Journal Plus, 2021
Background: P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied.
Xuxiao Ye, Jessica J.P. Shami, Vincent K.C. Yan, Wei Kang, Joseph E. Blais, Jiaxi Zhao, Wallis C.Y. Lau, Li Wei, Ian C.K. Wong, Esther W. Chan   +9 more
doaj   +1 more source